{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:08:32Z","timestamp":1770433712756,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["[2024-1-2182]"],"award-info":[{"award-number":["[2024-1-2182]"]}]},{"name":"Laboratory for Clinical Medicine, Capital Medical University","award":["[SYLH2023-04]"],"award-info":[{"award-number":["[SYLH2023-04]"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-12384-2","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T03:34:57Z","timestamp":1767843297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of PD-1+ B cells and IgG+ plasma cells with clinical cure of hepatitis B following interferon therapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Jiangyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zichen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daqiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dacheng","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minyu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4204-1049","authenticated-orcid":false,"given":"Zhenhuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"issue":"10","key":"12384_CR1","first-page":"1452","volume":"26","author":"YZ Yin","year":"2006","unstructured":"Yin YZ, Chen XW, Li XM, Hou HY, Shi ZJ. Intrauterine HBV infection: risk factors and impact of HBV DNA. Nan Fang Yi Ke Da Xue Xue Bao. 2006;26(10):1452\u20134.","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"8","key":"12384_CR2","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","volume":"20","author":"YC Hsu","year":"2023","unstructured":"Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20(8):524\u201337. https:\/\/doi.org\/10.1038\/s41575-023-00760-9.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"12384_CR3","doi-asserted-by":"publisher","first-page":"e0122259","DOI":"10.1371\/journal.pone.0122259","volume":"10","author":"ML Yeh","year":"2015","unstructured":"Yeh ML, Peng CY, Dai CY, et al. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS ONE. 2015;10(4):e0122259. https:\/\/doi.org\/10.1371\/journal.pone.0122259.","journal-title":"PLoS ONE"},{"issue":"Suppl 1","key":"12384_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jvh.13150","volume":"26","author":"H Ren","year":"2019","unstructured":"Ren H, Huang Y. Effects of pegylated interferon-\u03b1 based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B. J Viral Hepat. 2019;26(Suppl 1):5\u201331. https:\/\/doi.org\/10.1111\/jvh.13150.","journal-title":"J Viral Hepat"},{"issue":"4","key":"12384_CR5","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","volume":"42","author":"EC Rosser","year":"2015","unstructured":"Rosser EC, Mauri C, Regulatory B. Cells: origin, phenotype, and function. Immunity. 2015;42(4):607\u201312. https:\/\/doi.org\/10.1016\/j.immuni.2015.04.005.","journal-title":"Immunity"},{"issue":"5","key":"12384_CR6","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/atm-21-409","volume":"9","author":"ZQ Wu","year":"2021","unstructured":"Wu ZQ, Tan L, Gan WQ, et al. The relationship between the clearance of HBsAg and the remodeling of B cell subsets in CHB patients treated with Peg-IFN-\u03b1. Ann Transl Med. 2021;9(5):414. https:\/\/doi.org\/10.21037\/atm-21-409.","journal-title":"Ann Transl Med"},{"issue":"12","key":"12384_CR7","doi-asserted-by":"publisher","first-page":"e0242559","DOI":"10.1371\/journal.pone.0242559","volume":"15","author":"Z Cao","year":"2020","unstructured":"Cao Z, Meng S, Zheng Y, et al. B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy. PLoS ONE. 2020;15(12):e0242559. https:\/\/doi.org\/10.1371\/journal.pone.0242559.","journal-title":"PLoS ONE"},{"issue":"4","key":"12384_CR8","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","volume":"66","author":"Z Cao","year":"2017","unstructured":"Cao Z, Liu Y, Ma L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. Hepatology. 2017;66(4):1058\u201366. https:\/\/doi.org\/10.1002\/hep.29213.","journal-title":"Hepatology"},{"issue":"6","key":"12384_CR9","doi-asserted-by":"publisher","first-page":"e0156200","DOI":"10.1371\/journal.pone.0156200","volume":"11","author":"C Aspord","year":"2016","unstructured":"Aspord C, Bruder Costa J, Jacob MC, et al. Remodeling of B-cell subsets in blood during pegylated IFN\u03b1-2a therapy in patients with chronic hepatitis B infection. PLoS ONE. 2016;11(6):e0156200. https:\/\/doi.org\/10.1371\/journal.pone.0156200.","journal-title":"PLoS ONE"},{"issue":"7","key":"12384_CR10","doi-asserted-by":"publisher","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita T, Kobayashi T, Mizumaki K, et al. BAFF Inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci Adv. 2018;4(7):eaas9944. https:\/\/doi.org\/10.1126\/sciadv.aas9944.","journal-title":"Sci Adv"},{"issue":"3","key":"12384_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1172\/JCI85113","volume":"127","author":"C Mauri","year":"2017","unstructured":"Mauri C, Menon M. Human regulatory B cells in health and disease: therapeutic potential. J Clin Invest. 2017;127(3):772\u20139. https:\/\/doi.org\/10.1172\/JCI85113.","journal-title":"J Clin Invest"},{"issue":"11","key":"12384_CR12","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","volume":"18","author":"GC Fanning","year":"2019","unstructured":"Fanning GC, Zoulim F, Hou J, et al. Therapeutic strategies for hepatitis B virus infection: towards a cure. Nat Rev Drug Discov. 2019;18(11):827\u201344. https:\/\/doi.org\/10.1038\/s41573-019-0037-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"12384_CR13","doi-asserted-by":"publisher","first-page":"2463569","DOI":"10.1080\/07853890.2025.2463569","volume":"57","author":"L Tan","year":"2025","unstructured":"Tan L, Mo Z, Gan W, Gao Z, Zhu J, Wu Z. The remodeling of B-cell subsets was correlated with the clearance of hepatitis B antigen during pegylated IFN \u03b1-2a therapy in CHB patients. Ann Med. 2025;57(1):2463569. https:\/\/doi.org\/10.1080\/07853890.2025.2463569.","journal-title":"Ann Med"},{"issue":"1","key":"12384_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.antiviral.2013.01.006","volume":"98","author":"TM Block","year":"2013","unstructured":"Block TM, Gish R, Guo H, et al. Chronic hepatitis B: what should be the goal for new therapies? Antiviral Res. 2013;98(1):27\u201334. https:\/\/doi.org\/10.1016\/j.antiviral.2013.01.006.","journal-title":"Antiviral Res"},{"issue":"12","key":"12384_CR15","first-page":"2648","volume":"35","author":"GQ Wang","year":"2019","unstructured":"Wang GQ, Wang FS, Zhuang H, Li TS, Zheng SJ, Zhao H, et al. Guidelines for the prevention and treatment of chronic hepatitis B (2019 edition). J Clin Hepatol. 2019;35(12):2648\u201369. [in Chinese].","journal-title":"J Clin Hepatol"},{"issue":"2","key":"12384_CR16","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jhep.2020.04.013","volume":"73","author":"I Tout","year":"2020","unstructured":"Tout I, Loureiro D, Mansouri A, et al. Hepatitis B surface antigen seroclearance: immune mechanisms, clinical impact, importance for drug development. J Hepatol. 2020;73(2):409\u201322. https:\/\/doi.org\/10.1016\/j.jhep.2020.04.013.","journal-title":"J Hepatol"},{"issue":"13","key":"12384_CR17","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","volume":"26","author":"FP Wu","year":"2020","unstructured":"Wu FP, Yang Y, Li M, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen\u2009\u2264\u20091500 IU\/mL: an observational study. World J Gastroenterol. 2020;26(13):1525\u201339. https:\/\/doi.org\/10.3748\/wjg.v26.i13.1525.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"12384_CR18","doi-asserted-by":"publisher","first-page":"ofaa208","DOI":"10.1093\/ofid\/ofaa208","volume":"7","author":"QL Zeng","year":"2020","unstructured":"Zeng QL, Yu ZJ, Shang J, et al. Short-term peginterferon-induced high functional cure rate in inactive chronic hepatitis B virus carriers with low surface antigen levels. Open Forum Infect Dis. 2020;7(6):ofaa208. https:\/\/doi.org\/10.1093\/ofid\/ofaa208.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"12384_CR19","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.kint.2018.10.028","volume":"95","author":"C Leibler","year":"2019","unstructured":"Leibler C, Thiolat A, Elsner RA, et al. Costimulatory Blockade molecules and B-cell-mediated immune response: current knowledge and perspectives. Kidney Int. 2019;95(4):774\u201386. https:\/\/doi.org\/10.1016\/j.kint.2018.10.028.","journal-title":"Kidney Int"},{"issue":"5","key":"12384_CR20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1053\/jhep.2001.28459","volume":"34","author":"S Nair","year":"2001","unstructured":"Nair S, Perrillo RP. Serum Alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology. 2001;34(5):1021\u20136. https:\/\/doi.org\/10.1053\/jhep.2001.28459.","journal-title":"Hepatology"},{"issue":"2","key":"12384_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.gastro.2018.08.061","volume":"156","author":"B Rehermann","year":"2019","unstructured":"Rehermann B, Thimme R. Insights from antiviral therapy into immune responses to hepatitis B and C virus infection. Gastroenterology. 2019;156(2):369\u201383. https:\/\/doi.org\/10.1053\/j.gastro.2018.08.061.","journal-title":"Gastroenterology"},{"issue":"1","key":"12384_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/0016-5085(87)90863-8","volume":"92","author":"CM Chu","year":"1987","unstructured":"Chu CM, Liaw YF. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic\/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology. 1987;92(1):220\u20135. https:\/\/doi.org\/10.1016\/0016-5085(87)90863-8.","journal-title":"Gastroenterology"},{"issue":"1","key":"12384_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","volume":"18","author":"LL Lu","year":"2018","unstructured":"Lu LL, Suscovich TJ, Fortune SM, et al. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46\u201361. https:\/\/doi.org\/10.1038\/nri.2017.106.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"12384_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/intimm\/dxu095","volume":"27","author":"GK Philips","year":"2015","unstructured":"Philips GK, Atkins M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int Immunol. 2015;27(1):39\u201346. https:\/\/doi.org\/10.1093\/intimm\/dxu095.","journal-title":"Int Immunol"},{"key":"12384_CR25","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.3c03899","author":"Y Li","year":"2023","unstructured":"Li Y, Liu X, Yu L, et al. Covalent LYTAC enabled by DNA aptamers for immune checkpoint degradation therapy. J Am Chem Soc. 2023. https:\/\/doi.org\/10.1021\/jacs.3c03899.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"12384_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/QAI.0000000000001887","volume":"80","author":"Y Ghiglione","year":"2019","unstructured":"Ghiglione Y, Trifone C, Salido J, et al. PD-1 expression in HIV-specific CD8\u2009+\u2009T cells before antiretroviral therapy is associated with HIV persistence. J Acquir Immune Defic Syndr. 2019;80(1):1\u20136. https:\/\/doi.org\/10.1097\/QAI.0000000000001887.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"12384_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","volume":"5","author":"MR Cook","year":"2019","unstructured":"Cook MR, Kim C. Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review. JAMA Oncol. 2019;5(7):1049\u201354. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6737.","journal-title":"JAMA Oncol"},{"issue":"2","key":"12384_CR28","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.3892\/mmr.2016.5396","volume":"14","author":"ZS Tang","year":"2016","unstructured":"Tang ZS, Hao YH, Zhang EJ, et al. CD28 family of receptors on T cells in chronic HBV infection: expression characteristics, clinical significance and correlations with PD-1 Blockade. Mol Med Rep. 2016;14(2):1107\u201316. https:\/\/doi.org\/10.3892\/mmr.2016.5396.","journal-title":"Mol Med Rep"},{"issue":"10","key":"12384_CR29","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1172\/JCI121957","volume":"128","author":"L Salimzadeh","year":"2018","unstructured":"Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1 Blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest. 2018;128(10):4573\u201387. https:\/\/doi.org\/10.1172\/JCI121957.","journal-title":"J Clin Invest"},{"issue":"1","key":"12384_CR30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jhep.2019.07.015","volume":"72","author":"N Le Bert","year":"2020","unstructured":"Le Bert N, Salimzadeh L, Gill US, et al. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. J Hepatol. 2020;72(1):34\u201344. https:\/\/doi.org\/10.1016\/j.jhep.2019.07.015.","journal-title":"J Hepatol"},{"issue":"12","key":"12384_CR31","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/leu.2016.226","volume":"30","author":"M Seifert","year":"2016","unstructured":"Seifert M, K\u00fcppers R. Human memory B cells. Leukemia. 2016;30(12):2283\u201392. https:\/\/doi.org\/10.1038\/leu.2016.226.","journal-title":"Leukemia"},{"key":"12384_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-immunol-041015-055531","volume":"35","author":"F Weisel","year":"2017","unstructured":"Weisel F, Shlomchik M. Memory B cells of mice and humans. Annu Rev Immunol. 2017;35:255\u201384. https:\/\/doi.org\/10.1146\/annurev-immunol-041015-055531.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"12384_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/ni752","volume":"3","author":"SW Martin","year":"2002","unstructured":"Martin SW, Goodnow CC. Burst-enhancing role of the IgG membrane tail as a molecular determinant of memory. Nat Immunol. 2002;3(2):182\u20138. https:\/\/doi.org\/10.1038\/ni752.","journal-title":"Nat Immunol"},{"issue":"8","key":"12384_CR34","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1182\/blood.v99.8.2905","volume":"99","author":"GH Underhill","year":"2002","unstructured":"Underhill GH, Minges Wols HA, Fornek JL, et al. IgG plasma cells display a unique spectrum of leukocyte adhesion and homing molecules. Blood. 2002;99(8):2905\u201312. https:\/\/doi.org\/10.1182\/blood.v99.8.2905.","journal-title":"Blood"},{"key":"12384_CR35","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513\u201345. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120231.","journal-title":"Annu Rev Immunol"},{"key":"12384_CR36","doi-asserted-by":"publisher","first-page":"606456","DOI":"10.3389\/fimmu.2020.606456","volume":"11","author":"C Mazewski","year":"2020","unstructured":"Mazewski C, Perez RE, Fish EN, Platanias LC. Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways. Front Immunol. 2020;11:606456. https:\/\/doi.org\/10.3389\/fimmu.2020.606456.","journal-title":"Front Immunol"},{"issue":"3","key":"12384_CR37","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/jvh.12418","volume":"23","author":"V Kim","year":"2016","unstructured":"Kim V, Abreu RM, Nakagawa DM, Baldassare RM, Carrilho FJ, Ono SK. Pegylated interferon Alfa for chronic hepatitis B: systematic review and meta-analysis. J Viral Hepat. 2016;23(3):154\u201369. https:\/\/doi.org\/10.1111\/jvh.12418.","journal-title":"J Viral Hepat"},{"key":"12384_CR38","doi-asserted-by":"publisher","first-page":"932388","DOI":"10.3389\/fimmu.2022.932388","volume":"13","author":"MW Dahlgren","year":"2022","unstructured":"Dahlgren MW, Plumb AW, Niss K, Lahl K, Brunak S, Johansson-Lindbom B. Type I interferons promote germinal centers through B cell intrinsic signaling and dendritic cell dependent Th1 and Tfh cell lineages. Front Immunol. 2022;13:932388. https:\/\/doi.org\/10.3389\/fimmu.2022.932388.","journal-title":"Front Immunol"},{"key":"12384_CR39","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3389\/fimmu.2012.00002","volume":"3","author":"JL Karnell","year":"2012","unstructured":"Karnell JL, Ettinger R. The interplay of IL-21 and BAFF in the formation and maintenance of human B cell memory. Front Immunol. 2012;3:2. https:\/\/doi.org\/10.3389\/fimmu.2012.00002.","journal-title":"Front Immunol"},{"key":"12384_CR40","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fimmu.2014.00065","volume":"5","author":"L Moens","year":"2014","unstructured":"Moens L, Tangye SG. Cytokine-mediated regulation of plasma cell generation: IL-21 takes center stage. Front Immunol. 2014;5:65. https:\/\/doi.org\/10.3389\/fimmu.2014.00065.","journal-title":"Front Immunol"},{"issue":"1","key":"12384_CR41","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2478\/jtim-2023-0010","volume":"11","author":"HJ Fu","year":"2023","unstructured":"Fu HJ, Zhou M, Huang ZH, Chen YX, Wu XX. Severe acute hepatitis of unknown origin in children: clinical issues of concern. J Transl Int Med. 2023;11(1):19\u201323. https:\/\/doi.org\/10.2478\/jtim-2023-0010.","journal-title":"J Transl Int Med"},{"key":"12384_CR42","doi-asserted-by":"publisher","unstructured":"Hudu SA, Shinkafi SH, Jimoh AO. A critical review of diagnostic and prognostic markers of chronic hepatitis B infection. Med Rev (2021). 2024;4(3):225\u2013234. https:\/\/doi.org\/10.1515\/mr-2024-0022.","DOI":"10.1515\/mr-2024-0022"},{"issue":"4","key":"12384_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2478\/jtim-2023-0118","volume":"11","author":"JH Choi","year":"2023","unstructured":"Choi JH, Jun MS, Jeon JY, Kim HS, Kim YK, Jeon CH, Choi SH, Kim DS, Han MH, Oh JW. Global lineage evolution pattern of SARS-CoV-2 in Africa, America, Europe, and asia: a comparative analysis of variant clusters and their relevance across continents. J Transl Int Med. 2023;11(4):410\u201322. https:\/\/doi.org\/10.2478\/jtim-2023-0118.","journal-title":"J Transl Int Med"},{"issue":"4","key":"12384_CR44","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2478\/jtim-2023-0122","volume":"11","author":"J Xie","year":"2023","unstructured":"Xie J, Ye F, Deng X, Tang Y, Liang JY, Huang X, Sun Y, Tang H, Lei J, Zheng S, Zou Y. Circular RNA: a promising new star of vaccine. J Transl Int Med. 2023;11(4):372\u201381. https:\/\/doi.org\/10.2478\/jtim-2023-0122.","journal-title":"J Transl Int Med"},{"key":"12384_CR45","doi-asserted-by":"publisher","unstructured":"Guo M, Shang S, Li M, Cai G, Li P, Chen X, Li Q. Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis\/mechanisms of long COVID. Med Rev (2021). 2024;4(5):367\u2013383. https:\/\/doi.org\/10.1515\/mr-2024-0013.","DOI":"10.1515\/mr-2024-0013"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12384-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:56:02Z","timestamp":1770386162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12384-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12384"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12384-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"8 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided written informed consent at the time of enrollment, which included permission for storage and future research use of PBMC samples. The protocol and consent form for the study were approved by the research ethics committee of the Beijing You\u2019an Hospital, Capital Medical University, China ([2016]16), and conform to the principles of CFDA\/GCP and Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}